Recently, second-generation anti-VEGF agents, including brolucizumab, faricimab, and 8 mg aflibercept, have become available ...

Swiss medical regulators have approved a new malaria treatment for infants, offering hope to many in Africa KAMPALA, Uganda - ...

In people with recently diagnosed type 2 diabetes and no prior cardiovascular disease, self-reported physical activity ...

The company has a significant R&D arm in Ireland with numbers employed in R&D last year increasing from 224 to 270. Last year ...

According to Palo Alto, California-based Atropos, its researchers have already come up with an initial AI model that has ...

Novartis is partnering with Atropos Health to develop AI models that accelerate rare disease diagnosis, starting with a rare ...

Novartis Pharmaceuticals Canada Inc. is pleased to announce the successful conclusion of negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for the public reimbursement of Leqvio® ...

A former director of Chinook Therapeutics Inc. tipped off family and friends who traded stock ahead of an announcement that ...

Two VictORION studies will highlight Leqvio’s impact on patient quality of life, and as a cholesterol lowering monotherapyLp(a)FRONTIERS APHERESIS study will assess effect of pelacarsen on reducing ne ...

Votoplam (PTC518) for Huntington's Disease shows promising phase 2 results; a key FDA meeting in Q4 2025 could enable ...

The companies will develop AI models trained on real-world data to help identify and diagnose patients with paroxysmal nocturnal hemoglobinuria.